Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 193 |
| Active Pipeline (Recruiting Now) | 97 (66) |
| Completed vs Stopped Early | 63 / 33 (17.1%) |
| Median Closed Actual Enrollment | 33 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Johns Hopkins Hospital and Kimmel Cancer Center | Baltimore, MD | 165 |
| Sibley Memorial Hospital | Washington D.C, DC | 8 |
| Huntsman Cancer Institute at University of Utah | Salt Lake City, UT | 7 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07228104 | Adjuvant Steroid Outcomes in Idiopathic Subglottic Stenosis | Phase III | RECRUITING |
| NCT05836987 | The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase III | RECRUITING |
| NCT05537220 | Oral N-acetylcysteine for Retinitis Pigmentosa | Phase III | ACTIVE NOT RECRUITING |
| NCT04323800 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | Phase II | COMPLETED |
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | Phase III | TERMINATED |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johns Hopkins Medicine across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Johns Hopkins University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.